Mirum Pharmaceuticals Financials
This page shows Mirum Pharmaceuticals (MIRM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Mirum Pharmaceuticals has an operating margin of -26.0%, meaning the company retains $-26 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -58.6% the prior year.
Mirum Pharmaceuticals's revenue surged 80.8% year-over-year to $336.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Mirum Pharmaceuticals has a moderate D/E ratio of 1.97. This balance of debt and equity financing earns a leverage score of 38/100.
With a current ratio of 3.10, Mirum Pharmaceuticals holds $3.10 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Mirum Pharmaceuticals's free cash flow margin of 2.8% results in a low score of 14/100. Capital expenditures of $993K absorb a large share of operating cash flow.
Mirum Pharmaceuticals passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Mirum Pharmaceuticals generates $-0.12 in operating cash flow ($10.3M OCF vs -$87.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Mirum Pharmaceuticals earns $-6.1 in operating income for every $1 of interest expense (-$87.6M vs $14.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Mirum Pharmaceuticals generated $336.9M in revenue in fiscal year 2024. This represents an increase of 80.8% from the prior year.
Mirum Pharmaceuticals's EBITDA was -$64.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 34.9% from the prior year.
Mirum Pharmaceuticals generated $9.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 113.1% from the prior year.
Mirum Pharmaceuticals reported -$87.9M in net income in fiscal year 2024. This represents an increase of 46.2% from the prior year.
Mirum Pharmaceuticals earned $-1.85 per diluted share (EPS) in fiscal year 2024. This represents an increase of 53.8% from the prior year.
Mirum Pharmaceuticals held $222.5M in cash against $0 in long-term debt as of fiscal year 2024.
Mirum Pharmaceuticals had 48M shares outstanding in fiscal year 2024. This represents an increase of 3.5% from the prior year.
Mirum Pharmaceuticals's operating margin was -26.0% in fiscal year 2024, reflecting core business profitability. This is up 32.6 percentage points from the prior year.
Mirum Pharmaceuticals's net profit margin was -26.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 61.6 percentage points from the prior year.
Mirum Pharmaceuticals invested $140.6M in research and development in fiscal year 2024. This represents an increase of 37.1% from the prior year.
Mirum Pharmaceuticals invested $993K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 811.0% from the prior year.
MIRM Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $133.0M+4.1% | $127.8M+14.5% | $111.6M+12.2% | $99.4M+27.7% | $77.9M+12.5% | $69.2M-0.5% | $69.6M+45.7% | $47.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $43.0M-6.7% | $46.1M0.0% | $46.0M+4.6% | $44.0M+34.8% | $32.7M+1.4% | $32.2M+4.2% | $30.9M+18.4% | $26.1M |
| SG&A Expenses | $61.9M-2.2% | $63.3M+9.7% | $57.7M+1.5% | $56.8M+15.5% | $49.2M+7.8% | $45.6M-1.2% | $46.2M+26.4% | $36.5M |
| Operating Income | $2.6M+152.2% | -$5.0M+67.1% | -$15.2M+37.3% | -$24.2M0.0% | -$24.2M+8.4% | -$26.5M+18.8% | -$32.6M-29.6% | -$25.1M |
| Interest Expense | $3.6M+0.5% | $3.6M-0.2% | $3.6M+0.5% | $3.6M+0.3% | $3.6M-0.2% | $3.6M | N/A | $3.6M |
| Income Tax | -$262K-165.2% | $402K-60.9% | $1.0M+278.6% | -$576K-190.7% | $635K+1.8% | $624K+177.3% | $225K-9.6% | $249K |
| Net Income | $2.9M+149.6% | -$5.9M+60.1% | -$14.7M+38.3% | -$23.8M+3.4% | -$24.6M+2.5% | -$25.3M+29.1% | -$35.7M-51.2% | -$23.6M |
| EPS (Diluted) | $0.05+141.7% | $-0.12+60.0% | $-0.30+38.8% | $-0.49+5.8% | $-0.52+3.7% | $-0.54+21.7% | $-0.69-21.1% | $-0.57 |
MIRM Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $785.1M+8.2% | $725.8M+5.2% | $690.2M+2.9% | $670.8M+1.5% | $660.8M+1.3% | $652.0M+0.8% | $646.6M-0.6% | $650.6M |
| Current Assets | $530.6M+17.0% | $453.4M+10.4% | $410.8M+4.6% | $392.8M+6.8% | $367.8M-5.6% | $389.5M+0.5% | $387.5M-0.3% | $388.6M |
| Cash & Equivalents | $282.0M+23.6% | $228.1M+7.7% | $211.8M-4.8% | $222.5M-4.6% | $233.2M-23.0% | $302.8M+5.8% | $286.3M-5.5% | $303.1M |
| Inventory | $24.0M+4.7% | $22.9M+2.3% | $22.4M+0.1% | $22.4M+9.6% | $20.4M-5.4% | $21.6M-3.2% | $22.3M+0.3% | $22.3M |
| Accounts Receivable | $107.1M+0.3% | $106.8M+11.5% | $95.9M+22.4% | $78.3M+29.5% | $60.4M+9.9% | $55.0M-19.1% | $68.0M+42.1% | $47.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $493.1M+4.8% | $470.7M+3.0% | $457.0M+2.7% | $445.1M+3.1% | $431.8M+3.5% | $417.4M+4.9% | $398.0M+4.3% | $381.6M |
| Current Liabilities | $160.4M+10.7% | $144.8M+13.5% | $127.6M+0.8% | $126.6M+12.7% | $112.3M+6.0% | $105.9M+21.6% | $87.1M+16.6% | $74.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $292.0M+14.5% | $255.2M+9.4% | $233.3M+3.4% | $225.6M-1.5% | $229.0M-2.4% | $234.6M-5.7% | $248.7M-7.6% | $269.1M |
| Retained Earnings | -$661.8M+0.4% | -$664.7M-0.9% | -$658.9M-2.3% | -$644.2M-6.3% | -$606.2M-4.2% | -$581.5M-4.5% | -$556.2M-6.8% | -$520.6M |
MIRM Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $39.7M+229.6% | $12.0M+714.0% | -$2.0M+61.3% | -$5.1M-33.3% | -$3.8M-125.0% | $15.2M+191.5% | -$16.6M+8.8% | -$18.2M |
| Capital Expenditures | $187K+48.4% | $126K+207.3% | $41K+105.0% | $20K-97.4% | $779K+5892.3% | $13K | $0 | $0 |
| Free Cash Flow | $39.5M+231.5% | $11.9M+695.1% | -$2.0M+60.7% | -$5.1M-11.0% | -$4.6M-130.1% | $15.2M+191.5% | -$16.6M+8.8% | -$18.2M |
| Investing Cash Flow | -$2.2M+66.3% | -$6.6M+59.1% | -$16.1M-2617.0% | $641K+100.9% | -$72.7M-559261.5% | -$13K+99.4% | -$2.0M+98.9% | -$182.8M |
| Financing Cash Flow | $16.1M+85.3% | $8.7M+36.6% | $6.4M+19.1% | $5.3M-26.8% | $7.3M+505.1% | $1.2M-32.2% | $1.8M-99.1% | $207.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MIRM Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 2.0%+5.9pp | -3.9%+9.7pp | -13.6%+10.8pp | -24.4%+6.8pp | -31.1%+7.1pp | -38.2%+8.6pp | -46.9%+5.8pp | -52.7% |
| Net Margin | 2.2%+6.8pp | -4.6%+8.6pp | -13.2%+10.8pp | -23.9%+7.7pp | -31.6%+4.9pp | -36.5%+14.8pp | -51.3%-1.9pp | -49.4% |
| Return on Equity | 1.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.4%+1.2pp | -0.8%+1.3pp | -2.1%+1.4pp | -3.5%+0.2pp | -3.7%+0.2pp | -3.9%+1.6pp | -5.5%-1.9pp | -3.6% |
| Current Ratio | 3.31+0.2 | 3.13-0.1 | 3.22+0.1 | 3.10-0.2 | 3.28-0.4 | 3.68-0.8 | 4.45-0.8 | 5.20 |
| Debt-to-Equity | 1.69-0.2 | 1.84-0.1 | 1.96-0.0 | 1.97+0.1 | 1.89+0.1 | 1.78+0.2 | 1.60+0.2 | 1.42 |
| FCF Margin | 29.7%+20.4pp | 9.3%+11.1pp | -1.8%+3.3pp | -5.1%+0.8pp | -5.9%-27.8pp | 22.0%+45.9pp | -23.9%+14.3pp | -38.2% |
Similar Companies
Frequently Asked Questions
What is Mirum Pharmaceuticals's annual revenue?
Mirum Pharmaceuticals (MIRM) reported $336.9M in total revenue for fiscal year 2024. This represents a 80.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mirum Pharmaceuticals's revenue growing?
Mirum Pharmaceuticals (MIRM) revenue grew by 80.8% year-over-year, from $186.4M to $336.9M in fiscal year 2024.
Is Mirum Pharmaceuticals profitable?
No, Mirum Pharmaceuticals (MIRM) reported a net income of -$87.9M in fiscal year 2024, with a net profit margin of -26.1%.
What is Mirum Pharmaceuticals's earnings per share (EPS)?
Mirum Pharmaceuticals (MIRM) reported diluted earnings per share of $-1.85 for fiscal year 2024. This represents a 53.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Mirum Pharmaceuticals's EBITDA?
Mirum Pharmaceuticals (MIRM) had EBITDA of -$64.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mirum Pharmaceuticals's operating margin?
Mirum Pharmaceuticals (MIRM) had an operating margin of -26.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Mirum Pharmaceuticals's net profit margin?
Mirum Pharmaceuticals (MIRM) had a net profit margin of -26.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Mirum Pharmaceuticals's free cash flow?
Mirum Pharmaceuticals (MIRM) generated $9.3M in free cash flow during fiscal year 2024. This represents a 113.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mirum Pharmaceuticals's operating cash flow?
Mirum Pharmaceuticals (MIRM) generated $10.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Mirum Pharmaceuticals's total assets?
Mirum Pharmaceuticals (MIRM) had $670.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Mirum Pharmaceuticals's capital expenditures?
Mirum Pharmaceuticals (MIRM) invested $993K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Mirum Pharmaceuticals spend on research and development?
Mirum Pharmaceuticals (MIRM) invested $140.6M in research and development during fiscal year 2024.
How many shares does Mirum Pharmaceuticals have outstanding?
Mirum Pharmaceuticals (MIRM) had 48M shares outstanding as of fiscal year 2024.
What is Mirum Pharmaceuticals's current ratio?
Mirum Pharmaceuticals (MIRM) had a current ratio of 3.10 as of fiscal year 2024, which is generally considered healthy.
What is Mirum Pharmaceuticals's debt-to-equity ratio?
Mirum Pharmaceuticals (MIRM) had a debt-to-equity ratio of 1.97 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mirum Pharmaceuticals's return on assets (ROA)?
Mirum Pharmaceuticals (MIRM) had a return on assets of -13.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Mirum Pharmaceuticals's Piotroski F-Score?
Mirum Pharmaceuticals (MIRM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mirum Pharmaceuticals's earnings high quality?
Mirum Pharmaceuticals (MIRM) has an earnings quality ratio of -0.12x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mirum Pharmaceuticals cover its interest payments?
Mirum Pharmaceuticals (MIRM) has an interest coverage ratio of -6.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.